Leaders with the Lipoprotein(a) Foundation and the European Atherosclerosis Society (EAS) recently established an official partnership to increase awareness of inherited cardiovascular disease and genetic risk factors.
High lipoprotein(a) levels are a sign of independent, genetic risk factors that a patient could develop early cardiovascular disease. Increasing awareness about the illness and its various risk factors will help the public to be diagnosed more quickly and receive treatments on a more timely basis.
“The mission of the Lipoprotein(a) Foundation is to empower patients and prevent cardiovascular events due to high Lipoprotein(a) through proper testing and diagnosis,” Sandra Tremulis, founder of the foundation, said. “Previously, our reach has predominantly been supporting patients and their families in the United States. We are extremely proud to expand our horizons to Europe through this partnership with the European Atherosclerosis Society. We look forward to collaborating with the EAS to continue raising awareness and working towards the development of specific treatments for high Lipoprotein(a).”
In the partnership, EAS President Alberico Catapano will be included in a team of other world-leading experts on Lipoprotein(a). They will comprise the foundation’s worldwide Scientific Advisory Board.
“The EAS is pleased to officially partner with the Lipoprotein(a) Foundation to collaborate on a common goal of raising awareness for inherited cardiovascular disease and the risk of early disease associated with Lp(a),” Catapano said. “Our strategic priorities are aligned around education and empowering physicians and patients and we expect this partnership will help us achieve greater success in reaching these goals.”
